Arvinas and Pfizer Announce Positive Topline Results from Phase …
6 days ago · NEW HAVEN, Conn. and NEW YORK, March 11, 2025 – Arvinas, Inc. (Nasdaq: ARVN) and Pfizer Inc. (NYSE: PFE) today announced positive topline results from the Phase …
Arvinas and Pfizer Announce Global Collaboration to Develop …
Jul 22, 2021 · Arvinas and Pfizer will jointly develop ARV-471 through a robust clinical program designed to position ARV-471 as an endocrine backbone therapy of choice across the breast …
Arvinas and Pfizer Announce Positive Topline Results from Phase …
6 days ago · Actual results or events could differ materially from the plans, intentions and expectations disclosed in the forward-looking statements Arvinas makes as a result of various …
Pfizer, Arvinas Post Mixed Late-Stage Breast Cancer Data for …
5 days ago · Pfizer and Arvinas’ investigational PRTOAC degrader vepdegestrant can improve progression-free survival in breast cancer patients—but only in those carrying a specific …
Arvinas and Pfizer Announce Positive Topline Results from Phase …
5 days ago · NEW HAVEN, Conn. and NEW YORK, March 11, 2025 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN) and Pfizer Inc. (NYSE: PFE) today announced positive topline …
Arvinas and Pfizer Announce Positive Topline Results from
5 days ago · --Arvinas, Inc. and Pfizer Inc. today announced positive topline results from the Phase 3 VERITAC-2 clinical trial evaluating vepdegestrant monotherapy versus fulvestrant in …
Arvinas gets positive breast cancer data, but finds differentiation a ...
6 days ago · Dive Brief: Arvinas lost more than half of its market value Tuesday morning after the Connecticut-based biotechnology company and partner Pfizer disclosed anticipated results …
Arvinas, Pfizer announce VERITAC-2 achieved primary endpoint …
5 days ago · Arvinas and Pfizer announced topline results from the Phase 3 VERITAC-2 clinical trial evaluating vepdegestrant monotherapy versus fulvestrant in adults with estrogen receptor …
Pfizer, Arvinas’ PROTAC posts mixed results in first phase 3 test
5 days ago · Pfizer and Arvinas’ estrogen receptor (ER) degrader has failed a key part of its first phase 3 test, although the companies have pointed to success in a subpopulation to suggest …
Arvinas and Pfizer Announce Positive Phase 3 VERITAC-2 Trial
5 days ago · Arvinas, Inc. and Pfizer Inc. announced positive results from the Phase 3 VERITAC-2 clinical trial, which evaluated vepdegestrant, an investigational oral PROTAC ER degrader, …
- Some results have been removed